Indometacin Crescent Pharma (Indometacin)

Indometacin belongs to the NSAID class and reversibly blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. By inhibiting these enzymes, it lowers the production of prostaglandins, which are chemicals that promote inflammation, pain, and fever. The reduction of prostaglandins leads to decreased swelling and discomfort.

The exact dose of Indometacin Crescent Pharma is determined by the prescribing clinician based on the patient’s specific condition, severity, age, and renal or hepatic function. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimizing risk.

Safety data for indometacin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Indometacin is a potent NSAID with strong anti‑inflammatory activity, often considered more effective for gout flares compared with some other NSAIDs. However, it may have a higher incidence of gastrointestinal and renal side effects, so clinicians weigh its efficacy against safety profiles when selecting an alternative such as ibuprofen or naproxen.

Indometacin Crescent Pharma should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually with a full glass of water. It can be taken with food or milk to lessen stomach irritation, but patients should follow the specific instructions provided by their prescriber regarding timing and any dose adjustments.

Serious risks include gastrointestinal ulceration or bleeding, acute kidney injury, severe liver dysfunction, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of abdominal pain, blood in stool, sudden changes in urine output, jaundice, or rash, and seek medical attention promptly if they occur.

Indometacin is contraindicated in individuals with known hypersensitivity to indometacin or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, severe renal or hepatic impairment, and patients in the third trimester of pregnancy. It should also be avoided in patients taking certain anticoagulants or lithium without close medical supervision.